Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xianling Liu

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
The Lancet. Oncology|December 9, 2024
Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective studyYu Zhao, Shan Xiong, Qin Ren, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Lancet (London, England)|October 19, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in ChinaXiaohua Wu, Yang Sun, Hongying Yang, et al.
Nature Communications|March 14, 2026
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trialYang Sun, Hongying Yang, Jing Wang, et al.
JAMA|May 31, 2024
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial, Wenfeng Fang, Yuanyuan Zhao, et al.
JAMA|June 17, 2026
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial, Wenfeng Fang, Yuanyuan Zhao, et al.
The New England Journal of Medicine|July 8, 2026
Ensartinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung CancerDongsheng Yue, Meijuan Huang, Pingping Song, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
The Lancet. Oncology|December 9, 2024
Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective studyYu Zhao, Shan Xiong, Qin Ren, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Lancet (London, England)|October 19, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in ChinaXiaohua Wu, Yang Sun, Hongying Yang, et al.
Nature Communications|March 14, 2026
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trialYang Sun, Hongying Yang, Jing Wang, et al.
JAMA|May 31, 2024
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial, Wenfeng Fang, Yuanyuan Zhao, et al.
JAMA|June 17, 2026
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial, Wenfeng Fang, Yuanyuan Zhao, et al.
The New England Journal of Medicine|July 8, 2026
Ensartinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung CancerDongsheng Yue, Meijuan Huang, Pingping Song, et al.
Pageof 12